Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NMT1 | P30419 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2776680 | 0.98 | HTR1A (0.50) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| SCHEMBL13234945 | 0.91 | HTR2C (0.55) | HTR1ASLC6A2SLC6A3HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL2943264 | 0.89 | HTR2C (0.54) | HTR1ASLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL30752830 | 0.88 | PKM (0.45) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| SCHEMBL262176 | 0.88 | PKM (0.45) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| SCHEMBL473045 | 0.87 | HTR1A (0.51) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| Tert-Butyl Formate SCHEMBL27805796 | 0.86 | UTS2R (0.43) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL3140594 | 0.86 | HTR1A (0.50) | HTR1ASLC6A2SLC6A3IKBKBCHUK | |
| SCHEMBL16335376 | 0.85 | PKM (0.42) | SLC6A4 | |
| SCHEMBL941030 | 0.83 | SLC6A2 (0.58) | HTR1ASLC6A2SLC6A3HRH1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102046618-A | Hydroxyquinoxalinecarboxamide derivative | DAIICHI SANKYO CO LTD | 2011-05-04 | — | — | CN | disclosed |
| US-20100004287-A1 | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20100004287-A1 | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-04-16 | — | — | US | disclosed |
| WO-2007134457-A1 | CYCLIC AMINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| CN-1681503-A | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1539159-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099200-A1 | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | HTR1A 2883/4885SLC6A2 4749/4885SLC6A3 4660/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | HTR1A 2823/4885SLC6A2 2472/4885SLC6A3 2745/4885 |
| US-20100004287-A1 | Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, CPT1A | HTR1A 1930/4885SLC6A2 3390/4885SLC6A3 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.